ClinicalTrials.gov ID: NCT06027554
Status: Recruiting
Sponsor: University of Connecticut (UConn Health)
Study Type: Interventional

Summary:
This trial investigates the effects of MitoQ supplementation on vascular function, oxidative stress, mobility, and cognitive performance in frail and non‑frail older adults.

🔗 View on ClinicalTrials.gov:
https://clinicaltrials.gov/study/NCT06027554

ClinicalTrials.gov ID: NCT06424756
Status: Recruiting
Sponsor: University of Georgia
Study Type: Interventional (Phase 2)

Summary:
This study investigates the role of mitochondrial oxidative stress in endothelial function using MitoQ and comparator compounds in healthy adult populations.

🔗 View on ClinicalTrials.gov:
https://clinicaltrials.gov/study/NCT06424756

ClinicalTrials.gov ID: NCT05886816
Status: Recruiting
Sponsor: University of Texas Southwestern Medical Center
Phase: Phase 2

This study assesses mitoquinone/mitoquinol mesylate as a post‑exposure prophylactic intervention to reduce the development or severity of COVID‑19 following high‑risk exposure.
View on ClinicalTrials.gov.

ClinicalTrials.gov ID: NCT04267926
Status: Completed
Sponsor: Portland VA Health Care System

This completed, placebo‑controlled study evaluated whether oral MitoQ supplementation influenced fatigue outcomes in individuals living with multiple sclerosis.
View on ClinicalTrials.gov.

ClinicalTrials.gov ID: NCT04026711
Status: Completed
Sponsor: University of Vermont

This randomized, placebo‑controlled clinical trial investigated whether MitoQ supplementation affected airway reactivity and inflammatory markers in obese adults with poorly controlled asthma.
View on ClinicalTrials.gov.

ClinicalTrials.gov ID: NCT04109820
Status: Recruiting
Sponsor: University of Pittsburgh
Study Type: Interventional

This study examines whether short-term oral MitoQ supplementation influences platelet activation and mitochondrial reactive oxygen species measures in people with sickle cell anemia and healthy controls.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04109820

ClinicalTrials.gov ID: NCT06351683
Status: Recruiting
Sponsor: Iman Al‑Naggar, PhD (UConn Health)
Study Type: Interventional

This randomized study evaluates whether mitoquinol mesylate (MitoQ) taken daily for four months affects lower urinary tract symptoms (e.g., urgency, frequency) in women aged 50+ with metabolic syndrome, compared with placebo.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06351683

ClinicalTrials.gov ID: NCT07229261
Status: Not yet recruiting
Sponsor: Medical College of Wisconsin
Study Type: Interventional

This study evaluates MitoQ (mitoquinol mesylate) versus placebo in people with preeclampsia, with vascular function measures (e.g., flow-mediated dilation) and placental assessments described in the record.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07229261

ClinicalTrials.gov ID: NCT06409949
Status: Recruiting
Sponsor: University of Nebraska
Study Type: Interventional

This study investigates whether six months of MitoQ supplementation is associated with changes in walking ability, daily activity, quality of life, and calf muscle-related measures in people with peripheral artery disease and intermittent claudication.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06409949

ClinicalTrials.gov ID: NCT07142096
Status: Recruiting
Sponsor: Université Catholique de Louvain
Study Type: Interventional

This “window of opportunity” study is described as validating biomarkers in blood and tumor biopsy in people with triple negative breast cancer after a course of MitoQ treatment.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07142096

ClinicalTrials.gov ID: NCT06191965
Status: Recruiting
Sponsor: McLean Hospital
Study Type: Interventional

This randomized, double-blind, placebo-controlled study evaluates oral MitoQ supplementation as an adjunctive intervention, with cognition and related outcomes described in the record for early-phase schizophrenia-spectrum disorders and mitochondrial dysfunction markers.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06191965

ClinicalTrials.gov ID: NCT07406243
Status: Not yet recruiting
Sponsor: Colorado State University
Study Type: Interventional

This trial evaluates daily MitoQ versus placebo over three months and assesses cerebrovascular (brain artery) function in postmenopausal women as described in the record.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07406243

ClinicalTrials.gov ID: NCT05373043
Status: Recruiting
Sponsor: VA Office of Research and Development
Study Type: (not visible in extracted snippet)

The record describes a study focused on long-term consequences of COVID-19 and rehabilitation approaches, including an exercise-based rehabilitation component with mitochondria-targeted antioxidant supplementation (Mito‑Q) described in the registry text.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05373043

ClinicalTrials.gov ID: NCT07244809
Status: Recruiting
Sponsor: University of Iowa
Study Type: (not visible in extracted snippet)

This study examines whether mitochondrial oxidative stress contributes to impaired vascular function among young adults with early life adversity and whether reducing mitochondrial oxidative stress influences vascular and stress-response outcomes described in the registry record.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07244809

ClinicalTrials.gov ID: NCT07228208
Status: Not yet recruiting
Sponsor: Medical College of Wisconsin
Study Type: Interventional

This study evaluates whether impaired endothelial function and oxidative/cellular damage mechanisms contribute to exaggerated blood pressure responses during exercise in Type 2 diabetes, using MitoQ versus placebo as listed in the record.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07228208

ClinicalTrials.gov ID: NCT06424756
Status: Recruiting
Sponsor: University of Georgia
Study Type: Interventional

This trial investigates whether mitochondria-derived oxidative stress contributes to vascular dysfunction and includes MitoQ and placebo arms (and comparator agents listed in the record) in healthy adult participants.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06424756

ClinicalTrials.gov ID: NCT02966665
Status: Recruiting
Sponsor: Russell Richardson (University of Utah)
Study Type: (not visible in extracted snippet)

This registry record describes a broader study program examining vascular function changes with advancing age and in multiple disease states, with several vasoactive pathways of interest (e.g., NO and oxidative stress) described in the record.
View on ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02966665